Gilead Sciences Inc. (GILD) has gapped open sharply higher Thursday morning and is now up 4.07 at $57.70. The stock has broken out past resistance and has set a new high for the year.
Bristol-Myers Squibb (BMY) announced after the bell Wednesday that it has suspended study drug administration in an ongoing Phase II study of BMS-986094, a nucleotide polymerase inhibitor in development for the treatment of hepatitis C.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.